Abstract 4523
Background
Chemotherapy (chemo) efficacy may be limited due to damage to hematopoietic stem and progenitor cells (HSPCs) leading to multi-lineage myelosuppression. Trila is an iv CDK4/6 inhibitor in development to preserve HSPC and immune system function during chemo (myelopreservation). Preclinically, transient trila-induced G1 arrest renders HSPCs resistant to chemo cytotoxicity, leading to faster hematopoietic recovery and enhanced anti-tumor immunity. In a randomized, placebo-controlled, double-blind Phase 2 trial (NCT02499770), the addition of trila to etoposide/carboplatin (EP) in ES-SCLC patients showed multi-lineage myelopreservation, fewer supportive care interventions and dose reductions, and encouraging duration of response and progression free survival. Peripheral blood immunophenotyping was performed to characterize the effects of trila on the immune system.
Methods
Whole blood from patients in the EP + trila or EP + placebo arms was collected at baseline, during, and after treatment for flow cytometry analyses of monocytes, T, B, NK, dendritic, and myeloid-derived suppressor cells. T cells were also stimulated ex vivo to evaluate their ability to produce cytokines upon activation.
Results
Preliminary analyses indicate that B cells were significantly depleted during treatment with EP + placebo, but not with EP + trila. In addition to an increase in total CD8+ cells during treatment, EP + trila resulted in a larger population of activated CD8+ T cells, and fewer regulatory T cells which is consistent with a more robust immune response. Further analyses of trila’s effect on other immune cell types is ongoing.
Conclusions
These clinical trial findings demonstrate that in addition to preserving neutrophil and red blood cell lineages, adding trila to EP treatment can preserve B cells and enhance T lymphocyte function. In preclinical models, trila similarly enhanced activity of intra-tumor T cells, leading to superior anti-tumor efficacy when combined with chemo + anti-PDL1. A Phase 2 study to assess safety and efficacy of trila or placebo with EP and atezolizumab in first-line ES-SCLC has completed enrollment (NCT03041311).
Clinical trial identification
NCT02499770.
Legal entity responsible for the study
Delaware.
Funding
G1 Therapeutics.
Editorial Acknowledgement
Disclosure
J.A. Sorrentino, A. Lai, R.K. Malik, P.J. Roberts, S. Adler, J.M. Antal: Employee: G1 Therapeutics. J.M. Weiss: Financial support to institution: AstraZeneca, Celgene, Merck; Advisory board: AstraZeneca, Celgene, Boston Biomedical. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract